Series

Fallout Continues After Aducanumab Approval

Two weeks after the FDA gave the nod to aducanumab, the aftershocks continue to reverberate. Critics are lambasting the agency, three members of its advisory committee resigned, and the drug’s cost has ignited calls for pricing reform. Meanwhile, Alzheimerologists are split, with some applauding the first disease-modifying therapy and others worrying it could dampen research into other drugs. All bemoan the broad label and agree that the drug’s clinical rollout will be challenging.